[Skip to Navigation]
Views 305
Citations 0
Comment & Response
April 30, 2020

Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

Author Affiliations
  • 1AstraZeneca, Cambridge, United Kingdom
  • 2AstraZeneca, Gaithersburg, Maryland
JAMA Oncol. 2020;6(7):1115-1116. doi:10.1001/jamaoncol.2020.0637

To the Editor We read with interest the meta-analysis by Duan et al1 assessing differences in outcomes between programmed cell death 1 (PD-1) vs programmed cell death ligand 1 (PD-L1) inhibitors in the treatment of patients with cancer. We agree that this is a clinically significant question for which indirect comparison may play a role in the absence of head-to-head trials. However, there were limitations to this analysis that, despite its compliance with PRISMA guidelines, suggest the authors’ conclusions (ie, superiority in efficacy of PD-1 over PD-L1 inhibitors) are not well supported.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words